About: Silodosin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Silodosin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Silodosin is an α1-adrenoceptor antagonist that is selective for the prostate. Silodosin is for symptomatic treatment of benign prostatic hyperplasia. FDA approved Oct 9, 2008. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4A17-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/dosage/271B4A18-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Yoshida M, Homma Y, Kawabe K: Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2007 Dec;16(12):1955-65. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18042003 # Yamada S, Kato Y, Okura T, Kagawa Y, Kawabe K: Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol Pharm Bull. 2007 Jul;30(7):1237-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17603160 (en)
http://linked.open...gy/drugbank/group	approved (en)
http://linked.open...drugbank/halfLife	Silodosin = 13.3 ± 8.07 hours; KMD-3213G = 24 hours; (en)
http://linked.open...ugbank/indication	Treatment for symptomatic relief of benign prostatic hyperplasia (en)
sameAs	Silodosin
Title	Silodosin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/bindingdb/50160154 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/chemspider/4471557 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/drugbank/DB06207 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/kegg-drug/D01965 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/national-drug-code-directory/54868-6173-0 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/pharmgkb/PA165291889 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/pubchem-compound/5312125 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/pubchem-substance/7849027 http://linked.opendata.cz/resource/drugbank/drug/DB06207/identifier/wikipedia/Silodosin
http://linked.open...mechanismOfAction	Benign prostate hyperplasia (BPH), or an enlarged prostate, is a condition found only in men and is characterized by a non-cancerous enlargement of the prostate gland. Symptoms of BPH include urinary difficulty, urinary frequency and an inability to complete bladder emptying. Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate, [urethrea and bladder trigone in the lower urinary tract]. Blocking these receptors relaxes the smooth muscles, resulting in an improvement in urine flow and a reduction in BPH symptoms. The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ activity while minimizing the potential for blood pressure effects. [Watson Pharmaceutical Inc. Press release] Silodosin is alpha 1A-adrenoceptor selective antagonist which inhibits sympathetic nerve stimulation and relaxation of smooth muscle tone in the lower urinary tract which relieves the pressure from contraction of smooth muscle. The reduction of intraurethral pressure improves voiding and storage issues associated with BPH. (en)
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/5387603 http://linked.opendata.cz/resource/drugbank/patent/5403847
http://linked.open...outeOfElimination	Fecal (54.9%); Renal (33.5%) (en)
http://linked.open.../drugbank/synonym	KAD 3213 (en) KMD 3213 (en) Rapaflo (en) Urief (en)
http://linked.open...drugbank/toxicity	Most common adverse reactions (incidence > 2%) are retrograde ejaculation, dizziness, diarrhea, orthostatic hypotension, headache, nasopharyngitis, and nasal congestion. (en)
http://linked.open...umeOfDistribution	49.5 L (en)
http://linked.open...k/foodInteraction	The effect of a moderate fat, moderate calorie meal was variable and decreased silodosin Cmax by approximately 18 − 43% and AUC by 4 − 49% (en)
http://linked.open...nk/proteinBinding	97% bound to protein (en)
foaf:page	http://www.drugs.com/cdi/silodosin.html http://www.rxlist.com/rapaflo-capsules-drug.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4A1D-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B4A23-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B4A22-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4A1F-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4A20-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B4A21-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B4A1B-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4A33-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4A19-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4A1C-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B4A1A-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Silodosin
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4A29-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4A2A-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B4A24-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B4A25-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4A27-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B4A26-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4A28-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Quickly absorbed and has a bioavailability of 32% at 8mg/day (therapeutic dose). When 8 mg of silodosin is taken once daily with food, the pharmacokinetic parameters are as follows: Cmax = 61.6 ± 27.54 ng/mL; Tmax = 2.6 ± 0.90 hours; AUC (0h-24h) = 373 ng•hr/ml. The AUC of its metabolite, KMD3213G, is four times greater than silodosin. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	160970-54-7 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...rugbank/clearance	Plasma clearance = 10 L/h (en)
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4A2F-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B4A31-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B4A32-363D-11E5-9242-09173F13E4C5
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B4A34-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4A2E-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4A2D-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4A30-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4A1E-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B4A2B-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4A2C-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software